-
341por Yu, Chen, Littleton, Sejiro, Giroux, Nicholas S., Mathew, Rose, Ding, Shengli, Kalnitsky, Joan, Yang, Yuchen, Petzold, Elizabeth, Chung, Hong A., Rivera, Grecia O., Rotstein, Tomer, Xi, Rui, Ko, Emily R., Tsalik, Ephraim L., Sempowski, Gregory D., Denny, Thomas N., Burke, Thomas W., McClain, Micah T., Woods, Christopher W., Shen, Xiling, Saban, Daniel R.“…COVID-19 samples were processed under Biosafety level 2 (BSL-2) with aerosol management enhancement or BSL-3 in the Duke Regional Biocontainment Laboratory, which received partial support for construction from NIH/NIAID (UC6AI058607).…”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
342por Widera, Marek, Westhaus, Sandra, Rabenau, Holger F., Hoehl, Sebastian, Bojkova, Denisa, Cinatl, Jindrich, Ciesek, Sandra“…Laboratory work with SARS-CoV-2 in a laboratory setting was rated to biosafety level 3 (BSL-3) biocontainment level. However, certain research applications in particular in molecular biology require incomplete denaturation of the proteins, which might cause safety issues handling contaminated samples. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
343por Werner, Katharina A., Poehlein, Anja, Schneider, Dominik, El-Said, Khaliel, Wöhrmann, Michael, Linkert, Isabel, Hübner, Tobias, Brüggemann, Nicolas, Prost, Katharina, Daniel, Rolf, Grohmann, Elisabeth“…A quarter of the isolated BSL-2 strains exhibited multiresistance to different classes of antibiotics. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
344por Gourdelier, Manon, Swain, Jitendriya, Arone, Coline, Mouttou, Anita, Bracquemond, David, Merida, Peggy, Saffarian, Saveez, Lyonnais, Sébastien, Favard, Cyril, Muriaux, Delphine“…This work provides new insights on the use of non-fluorescent and fluorescent VLPs to study and visualize the SARS-CoV-2 viral life cycle in a safe environment (BSL-2 instead of BSL-3). Moreover, optimized SARS-CoV-2 VLP production can be further adapted to vaccine design strategies.…”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
345por Stokes, John V., Levin, Michael L., Cross, Claire E., Ross, Anne‐Marie L., Snellgrove, Alyssa N., Willeford, Bridget V., Alugubelly, Navatha, Varela‐Stokes, Andrea S.“…This unit provides the basic protocols necessary to establish, maintain, and utilize a guinea pig‐tick‐Rickettsia model for monitoring the course of infection and immune response to an infection by spotted fever group Rickettsia (SFGR) that can be studied at biosafety level 2 (BSL‐2) and arthropod containment level 2 (ACL‐2); adaptations must be made for BSL‐3 agents. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
346“…Avian models of West Nile virus (WNV) disease have become pivotal in the study of infection pathogenesis and transmission, despite the intrinsic constraints that represents this type of experimental research that needs to be conducted in biosecurity level 3 (BSL3) facilities. This review summarizes the main achievements of WNV experimental research carried out in wild birds, highlighting advantages and limitations of this model. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
347
-
348por Yu, Jiarong, Lv, Xinbo, Yang, Zijun, Gao, Shengbin, Li, Changming, Cai, Yumei, Li, Jinming“…Nipah disease is a highly fatal zoonosis which is caused by the Nipah virus. The Nipah virus is a BSL-4 virus with fruit bats being its natural host. …”
Publicado 2018
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
349Crimean-Congo Hemorrhagic Fever Virus: Current Advances and Future Prospects of Antiviral Strategies“…Currently, climate change and globalization have increased the transmission risk of this biosafety level (BSL)-4 virus. The treatment options of CCHFV infection remain limited and there is no FDA-approved vaccine or specific antivirals, which urges the identification of potential therapeutic targets and the design of CCHF therapies with greater effort. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
350por Xiao, Zhen, Cruz, Marcos, Hojo, Emi, Eungpinichpong, Wichai, Wang, Xingze, Xiao, Li, Chatchawan, Uraiwan, Hu, Ying, Roberts, Neil“…Measurements of Posture (C7 to Wall Distance (C7WD), Standing Height (SH), Flexibility (Back Scratch of Left and Right arms (BSL and BSR) and Chair Sit and Reach of Left and Right legs (CSRL and CSRR), Gait (Timed Up and Go (TUG)), and Cognition (Barthel Activities of Daily Living Index (BADL) and Rosenberg Self Esteem Scale (RSES) questionnaires) were recorded for each group prior to, on day 1, week 4, and week 8 of the SSG training. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
351por Patterson, Patricia, Socías, Eugenia, Pryluka, Daniel, Lapadula, Pablo, Pérez, Héctor, Cahn, Pedro“…In multivariate analysis, no statistical significant associations were observed between either development of toxicity or treatment discontinuation and gender, chronic hepatitis, age or CD4-cell count at BSL or at switch (all p>0.05). CONCLUSIONS: In our study, switching to a NVP-based regimen in patients with undetectable VL was associated with a low incidence of skin or liver toxicity, and treatment discontinuation. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
352por Ssengooba, Willy, Gelderbloem, Sebastian J, Mboowa, Gerald, Wajja, Anne, Namaganda, Carolyn, Musoke, Philippa, Mayanja-Kizza, Harriet, Joloba, Moses Lutaakome“…Herein, we share our experience of establishing a BSL-3 culture facility in Uganda as well as 3-years performance indicators and post-TB vaccine trials (pioneer) and funding experience of sustaining such a facility. …”
Publicado 2015
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
353“…METHODS & PROCEDURES: Participants were deaf children aged 6–11 years (N = 106, comprising 69 users of spoken English, 29 users of BSL and eight users of Sign Supported English—SSE) compared with hearing children (N = 120) of the same age who used spoken English. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
354por Diniz, Pedro, Abreu, Mariana, Lacerda, Diogo, Martins, António, Pereira, Hélder, Ferreira, Frederico Castelo, Kerkhoffs, Gino MMJ, Fred, Ana“…Regarding the predictive model, the average AUROC after cross-validation was 0.81 ± 0.10, and the BSL was 0.12, with the most important features relating to pre-injury match participation. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
355por Saito, Takeshi, Reyna, Rachel A., Taniguchi, Satoshi, Littlefield, Kirsten, Paessler, Slobodan, Maruyama, Junki“…Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
356por Das, Suchismita, Garver, Lindsey, Ramirez, Jose Ruiz, Xi, Zhiyong, Dimopoulos, George“…The entire experiment must be conducted in a BSL2 laboratory. Similar to Plasmodium falciparum infections, proper attire including gloves and lab coat must be worn at all times. …”
Publicado 2007
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
357por Tsunetsugu-Yokota, Yasuko“…In order to develop an effective vaccine and diagnostic tools, we prepared UV-inactivated SARS coronavirus on a large scale under the strict Biosafety Level 3 (BSL3) regulation. Our protocol for large-scale preparation of UV-inactivated SARS-CoV including virus expansion, titration, inactivation, and ultracentrifugation is applicable to any newly emerging virus we might encounter in the future.…”
Publicado 2007
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
358por Coughlan, Lynda“…This VSV-CoV-2-S platform allows virus neutralization assays to be performed at BSL-2 and also has applications as a candidate vectored vaccine to elicit protective immunity against SARS-CoV-2.…”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
359por Xiao, Chanchan, Qiu, Congling, Deng, Jieping, Ye, Jiezhou, Gao, Lijuan, Su, Jun, Luo, Oscar Junhong, Wang, Pengcheng, Chen, Guobing“…The use of aAPC and healthy donors means that only BSL2 lab conditions are needed. For details of the use and implementation of this protocol, please refer to Deng et al. (2021).…”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
360“…Women (65–85 years) had significantly better mean SR, BSR, BSL and SBE results compared with men (65–85 years). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto